ANNAPOLIS, MD—The Plasma Protein Therapeutics Association (PPTA) opposes New Jersey Senate Bill 2132 that imposes a new tax on therapies used to treat bleeding disorders such as hemophilia.
The Plasma Protein Therapeutics Association is pleased to announce substantive improvements to its Quality Standards for Excellence and Leadership (QSEAL)
The 2013 Plasma Protein Forum was held in Reston, Virginia on June 11-12.
The Plasma Protein Therapeutics Association (PPTA) commends the Preserving Access to Orphan Drugs Acts, bipartisan legislation that makes an important policy clarification and will remove a barrier to research and development of rare disease therapies.
April 16, 2013–The Plasma Protein Therapeutics Association (PPTA) recognizes World Hemophilia Day, an annual international event sponsored by the World Federation for Hemophilia (WFH) that seeks to raise awareness of people living with inherited bleeding disorders.
Last week, the President and Congress could not come to an agreement and on March 1, 2013 sequestration, $85 billion in across the board federal spending cuts, went into effect.
The Plasma Protein Therapeutics Association (PPTA) joins over 300 organizations in 56 countries in recognizing the 6th annual International Rare Disease Day on February 28.
The Plasma Protein Therapeutics Association (PPTA) is proud to announce that the Global Board of Directors elected Paolo Marcucci, as Chairman at its meeting in Brussels, Belgium today.
The Plasma Protein Therapeutics Association (PPTA) applauds the House of Representatives on yesterday's passage of the Medicare IVIG Access Act (H.R. 1845), which gives Medicare patients who suffer from primary immunodeficiency disease (PI) better access to lifesaving intravenous immune globulin (IVIG) therapy at home.
The Plasma Protein Therapeutics Association (PPTA) has awarded UNICAplasma, s. r. o. with International Quality Plasma Program (IQPP) certification for its plasma collection center in Prague.
